At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 62 enrolled
Drug / intervention
SAB-176 +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2a, Randomised, Double-blind, Placebo-controlled Study to Evaluate the Safety and Treatment Efficacy of SAB-176 (a Quadrivalent Anti-seasonal Influenza Immunoglobulin Product) in an H1N1 Challenge Model in Healthy Adult Participants
In Brief
A Phase 2 clinical trial evaluating SAB-176 and Placebo for Influenza A H1N1. Completed, enrolled 62 participants across 1 site.
Detailed Summary
Healthy adult participants will be challenged with the H1N1 Influenza virus and then treated with either SAB-176 or placebo.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsInfluenza A H1N1
CountriesUnited Kingdom
CollaboratorsHvivo
Timeline
Phase 2CompletedFinished
20222023202420252026
First PostedApr 2021
Enrollment StartJun 2021
Primary CompletionOct 2021
TodayJul 2026
First PostedApr 20, 2021
Enrollment StartJun 23, 2021
Primary CompletionOct 8, 2021
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 5.2 years ago
Interventions
SAB-176biological
Treatment of influenza
Placeboother
Placebo Control